Literature DB >> 11147124

Basic coating polymers for the colon-specific drug delivery in inflammatory bowel disease.

C S Leopold1, D Eikeler.   

Abstract

During acute attacks of inflammatory bowel disease, the luminal pH of the colon decreases significantly. This drop in pH can be exploited by developing coated dosage forms with acid-soluble coating polymers to achieve topical drug delivery to the colon. Two batches of minitablets, a conventional and a swellable formulation, were prepared by direct compression and coated with different amounts of either Eudragit E or AEA in a small coating pan. The release of the model drug dexamethasone from the coated tablets was measured spectrophotometrically at pH 2.0, 4.0, 5.0, and 6.8 and different stirring rates (100-200 rpm) to simulate the influence of pH and hydrodynamic stress on drug release. In general, lag times of drug release, determined as the time points of a 5% drug release, were longer with AEA-coated cores compared to those coated with Eudragit E, resulting from a lower polymer dissolution rate and water permeability of this film. In low pH media, drug release was dependent on the stirring rate because the onset of drug release is determined by the time required for dissolution of the basic polymer films. At pH 6.8, lag times from nonswelling tablets coated with Eudragit E, for which drug release only begins after complete erosion of the polymer film, are not significantly affected by hydrodynamic stress. Drug release from AEA-coated cores is determined by the slow drug diffusion through the polymer film. Lag times from tablets with swelling properties, for which drug release is induced by disruption of the basic polymer films due to water penetration and subsequent core swelling, are not significantly affected by hydrodynamic stress. Additional coating layers such as an intermediate hydroxypropylcellulose (HPC) layer and an enteric outer layer do not influence the lag times of drug release, nor does a 2-hr pretreatment of the entire dosage form in acidic media.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11147124     DOI: 10.1081/ddc-100102305

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  6 in total

1.  Development of sustained release capsules containing "coated matrix granules of metoprolol tartrate".

Authors:  Sabahuddin Siddique; Jasmina Khanam; Papiya Bigoniya
Journal:  AAPS PharmSciTech       Date:  2010-08-19       Impact factor: 3.246

2.  Synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting.

Authors:  Yi-Nuo Pang; Yan Zhang; Zhi-Rong Zhang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

3.  Electrolyte-stimulated biphasic dissolution profile and stability enhancement for tablets containing drug-polyelectrolyte complexes.

Authors:  Christoph Kindermann; Karin Matthée; Frank Sievert; Jörg Breitkreutz
Journal:  Pharm Res       Date:  2012-01-07       Impact factor: 4.200

4.  Orally Deliverable Dual-Targeted Pellets for the Synergistic Treatment of Ulcerative Colitis.

Authors:  Xiaomeng Tang; Meng Yang; Yongwei Gu; Liangdi Jiang; Yue Du; Jiyong Liu
Journal:  Drug Des Devel Ther       Date:  2021-09-29       Impact factor: 4.162

5.  Design and optimization of mefloquine hydrochloride microparticles for bitter taste masking.

Authors:  Punit P Shah; Rajashree C Mashru; Yogesh M Rane; Arti Thakkar
Journal:  AAPS PharmSciTech       Date:  2008-02-20       Impact factor: 3.246

6.  In Silico, In Vitro, and In Vivo Evaluation of Precipitation Inhibitors in Supersaturated Lipid-Based Formulations of Venetoclax.

Authors:  Niklas J Koehl; Laura J Henze; Harriet Bennett-Lenane; Waleed Faisal; Daniel J Price; René Holm; Martin Kuentz; Brendan T Griffin
Journal:  Mol Pharm       Date:  2021-04-23       Impact factor: 4.939

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.